What is Tenpoint Therapeutics?
Founded in 2020 and headquartered in Cambourne, United Kingdom, Tenpoint Therapeutics is a pioneering company focused on developing vision-restoring engineered cell-based therapeutics. The company is dedicated to fundamentally reshaping the future for individuals suffering from ocular diseases through innovative cell-based therapies and in vivo reprogramming techniques. This strategic focus positions Tenpoint Therapeutics at the forefront of regenerative medicine for vision impairment.
How much funding has Tenpoint Therapeutics raised?
Tenpoint Therapeutics has raised a total of $70M across 1 funding round:
Series A
$70M
Series A (2023): $70M with participation from F-Prime Capital Partners and British Patient Capital
Key Investors in Tenpoint Therapeutics
F-Prime Capital Partners
F-Prime Capital Partners is an investment firm established in 2002, focusing on healthcare and technology sectors. Their team of investors, engineers, doctors, and scientists provides strategic backing to companies poised for significant impact.
British Patient Capital
British Patient Capital, part of the British Business Bank, is a government-owned entity dedicated to supporting UK businesses. It specializes in providing access to finance, including equity, for innovative start-ups and growing companies across the nation.
What's next for Tenpoint Therapeutics?
The substantial enterprise-level funding indicates a critical growth phase for Tenpoint Therapeutics, likely enabling the company to advance its pipeline, scale operations, and potentially pursue clinical trials. This investment will be instrumental in accelerating the development and commercialization of its vision-restoring technologies, aiming to address unmet needs in the ophthalmology market and solidify its position as a leader in the field of ocular regenerative medicine.
See full Tenpoint Therapeutics company page
